Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors
文献类型：期刊论文
| 作者 | Yan, Yan2; Zhang, Li3,4; Zuo, Yun2; Qian, Heya2; Liu, Chang1 |
| 刊名 | ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
 |
| 出版日期 | 2020-11-13 |
| 卷号 | 68期号:6页码:15 |
| ISSN号 | 0004-069X |
| 关键词 | Immune checkpoints PD-1 PD-L1 Monoclonal antibody Immunotherapy |
| DOI | 10.1007/s00005-020-00601-6 |
| 通讯作者 | Zhang, Li(lz3@email.sc.edu) ; Liu, Chang(hichang813@uri.edu) |
| 英文摘要 | Programmed cell death protein 1 (PD-1) and its ligand PD-L1 are critical for the regulation of T cell exhaustion and activity suppression. Tumor cells expressing immune checkpoints including PD-L1 escape monitoring of T cells from the host immune system. Checkpoint inhibitors are highly promising therapies that function as tumor-suppressing factors via modulation of tumor cell-immune cell interactions as well as boosting T cell-mediated anti-tumor immunity. Notably, PD-1 or PD-L1 monoclonal antibody (mAb) has demonstrated promising therapeutic effects in clinical studies of many types of cancer. These mAbs have caused significant tumor regression with impressive anti-tumor response rates as well as a favorable safety profile in cancer patients. Furthermore, the combination of PD-1/PD-L1 mAbs with other types of anti-tumor agents has also developed to boost the anti-tumor responses and enhance therapeutic effects in cancer patients. This review clarifies the mechanisms of PD-1/PD-L1-mediated anti-cancer immune responses and some clinical studies of mAbs targeting PD-1/PD-L1. The challenges and future of PD-1/PD-L1 blockade therapy are also discussed. |
| WOS关键词 | PROGRAMMED DEATH-1 BLOCKADE ; T-CELL EXHAUSTION ; ANTI-PD-L1 ANTIBODY ; OPEN-LABEL ; B7 FAMILY ; PHASE-I ; ACQUIRED-RESISTANCE ; ADVANCED MELANOMA ; PD-1 BLOCKADE ; SINGLE-GROUP |
| 资助项目 | Social Development of Science and Technology Bureau of Zhangjiagang City[ZKS1734] ; Project of Diagnosis and Treatment Technology for Key Clinical Diseases of Suzhou[LCZX201617] |
| WOS研究方向 | Immunology |
| 语种 | 英语 |
| 出版者 | SPRINGER BASEL AG |
| WOS记录号 | WOS:000594672200002 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/296200]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Zhang, Li; Liu, Chang |
| 作者单位 | 1.Univ Rhode Isl, Coll Pharm, Kingston, RI 02881 USA 2.Soochow Univ, Affiliated Zhangjiagang Hosp, Zhangjiagang 215600, Jiangsu, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 4.Univ South Carolina, Coll Pharm, Columbia, SC 29208 USA |
| 推荐引用方式 GB/T 7714 | Yan, Yan,Zhang, Li,Zuo, Yun,et al. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors[J]. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS,2020,68(6):15. |
| APA | Yan, Yan,Zhang, Li,Zuo, Yun,Qian, Heya,&Liu, Chang.(2020).Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS,68(6),15. |
| MLA | Yan, Yan,et al."Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors".ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS 68.6(2020):15. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。